RICHMOND, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic
exoskeleton company, today announced it will host an Investor Day on December 6, 2016, in New York, NY. The presentation will begin
at 8:00 a.m. (Eastern Time) followed by a question and answer session, and is expected to end at approximately 10:30 a.m., with
product demonstrations also included in the morning session. The presentation will be webcast live and may be accessed via
the Ekso Bionics website at http://eksobionics.com under the Investor section. Materials accompanying the presentation
will also be posted within this section under "News / Events" following the event.
Presentations will be given by the following:
- Dylan Edwards, Ph.D., P.T., Director & Principal Investigator, Burke Rehabilitation & Research; Principal Investigator, WISE
Study
- Frank Hyland, M.S., P.T. Vice President of Rehabilitation Services and Administrator, Good Shepherd Rehabilitation
Hospital
- Russ Angold, President, Ekso Labs
For those unable to join the live webcast, a replay will be available following the event and can be accessed on
the Ekso Bionics website at http://eksobionics.com under the Investor section.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength,
endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon
its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso
Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to
enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended
to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under
the symbol EKSO. For more information, visit: www.eksobionics.com.
About Ekso™ GT
Ekso™ GT is the first exoskeleton cleared by the FDA for use with stroke and spinal cord injuries
from L5 to C7. The Ekso GT with smart Variable Assist™ (marketed as SmartAssist outside the U.S.) software is the only exoskeleton
available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s body,
challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to
mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped
patients take more than 55 million steps in over 120 rehabilitation institutions around the world.
Media Contact: Carrie Yamond/Rajni Dhanjani 212-867-1788 cyamond@lazarpartners.com Investor Contact: Debbie Kaster 415-937-5403 investors@eksobionics.com
